Business Wire

KIOXIA-CORPORATION

Share
Kioxia Presented Image Classification System Deploying Memory-Centric AI with High-capacity Storage at ECCV 2022

Kioxia Corporation, the world leader in memory solutions, has developed an image classification system based on Memory-Centric AI, an AI technology that utilizes high-capacity storage. The system classifies images using a neural network that refers to knowledge stored in external high-capacity storage; this avoids "catastrophic forgetting," one of the major challenges of neural networks, and allows knowledge to be added or updated without the loss of current knowledge. This technology was presented on October 25 at the oral session of European Conference on Computer Vision 2022 (ECCV 2022) in Tel Aviv, one of the top conferences in the field of computer vision[1].

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221101006375/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Image classification utilizing high-capacity storage (Graphic: Business Wire)

In conventional AI techniques, neural networks are trained to acquire knowledge by updating parameters called “weights.” Once fully trained, in order to acquire new knowledge a neural network must be either re-trained from the beginning or fine-tuned with new data. The former requires huge amounts of time and consumes significant energy costs, while the latter requires parameters to be updated and faces the catastrophic forgetting problem of losing the knowledge acquired in the past which leads to deterioration of classification accuracy.

To address the issues of cost and accuracy in neural network-based image classification systems, the new solution stores large amounts of image data, labels and image feature maps[2] as knowledge in a high-capacity storage. The neural network then classifies images by referring to that stored knowledge (Figure 1). Using this method, knowledge can be added or updated by adding newly obtained image labels and feature maps to the stored data. As there is no need to re-train or update weights, which may cause “catastrophic forgetting,” image classification can be maintained more accurately.

Furthermore, by using the data referred from the storage when the neural network classifies images, the basis for the classification results can be visualized, which is expected to improve the explainability of AI[3] and alleviate the black-box problem[4], in turn allowing the selective modification of knowledge sources. In addition, by analyzing the referred data, the contribution of each stored data can be evaluated according to the frequency of references.

Guided by its mission of "Uplifting the World with ‘Memory,’" Kioxia will continue to contribute to the development of AI and storage technologies by expanding Memory-Centric AI beyond image classification to other areas and promoting research and development of AI technology utilizing high-capacity storage.

About Memory-Centric AI

Introductory Video: https://youtu.be/lw8XKhviGJc
Memory-Centric AI, Part I: How Kioxia’s Top Engineers Are Developing an AI That Relies on Memory https://brand.kioxia.com/en-jp/articles/article25.html
Memory-Centric AI, Part II: An Internet of Memories: Brainstorming Uses for Memory-Centric AI https://brand.kioxia.com/en-jp/articles/article26.html

About ECCV

The European Conference on Computer Vision (ECCV) is one of the top conferences in the field of computer vision. In recent years, ECCV has established itself as a prime venue for the presentation of AI research papers including image classification, object detection, and other technologies using deep learning. The oral presentation acceptance rate was 2.7% in this year.

[1] Paper title: K. Nakata et. al., “Revisiting a kNN-based Image Classification System with High-capacity Storage”, European Conference on Computer Vision 2022 (ECCV 2022)
[2] Image feature maps: multidimensional (e.g., 1,024-dimensional) numerical data obtained through neural network operations
[3] Explainability of AI: possibly of explaining the basis and reasons of results predicted by AI in a way that can be interpreted by humans.
[4] Black-box problem: the process leading to the results predicted by AI is not interpretable to humans, making it a black box problem.

Company names, product names, and service names may be trademarks of third-party companies.

About Kioxia

Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with memory by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive and data centers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221101006375/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye